The 10 Year Health Plan set out how the government will address the long-standing challenge that cutting-edge HealthTech is not being used in the NHS , or is only available to patients in some parts ...
A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before ...
The faecal immunochemical test (FIT) detects small amounts of blood in poo, which can be a sign of bowel cancer. Bowel cancer is the second biggest cancer killer in the UK, affecting the large bowel ...
Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy TA1126 28 January 2026 28 January 2026 Concizumab for treating ...
Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...
This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care. NICE has also ...
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. Next review: This guidance will be ...
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
This guidance has been updated and replaced by osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results